NCT00694317

Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions

A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Roxane Laboratories · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was the bioequivalence of a Roxane Laboratories' Zaleplon Capsules, 10 mg, to Sonata ® Capsules, 10 mg (Jones Pharma) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design

Conditions

• Short Term Treatment of Insomnia

Interventions

Type	Name	Description
DRUG	Zaleplon	Short term treatment of insomnia

Timeline

• Start date: 2004-02-01
• Primary completion: 2004-02-01
• Completion: 2004-02-01
• First posted: 2008-06-10
• Last updated: 2018-01-23

Locations

1 site across 1 country: United States